verifi LUNG Test

Know the sample is right, before the biopsy ends.

A 5-minute rapid test to verify specimen sufficiency during the procedure.

verifi LUNG workstation, sample vials and portable reader by ROSE Diagnostics

*Products not FDA cleared or approved in any jurisdiction

Rethinking the lung biopsy

  • Too many lung biopsies have to be repeated.

    Up to 40% of lung biopsy samples are returned as insufficient for analysis.1

    Rack of stained biopsy slides
  • Lung cancer is the leading cause of cancer death in the U.S.

    About 229,000 new lung cancer cases are expected in the U.S. in 2026.2

    Chest CT scan on a clinical monitor
  • Every week before treatment counts.

    In stage I non-small cell lung cancer, 5-year survival was 43% when treatment began after 6 weeks, compared with 56% when it began within 6 weeks.3

    IV treatment bag
  • Our solution: the verifi LUNG Test

    A portable, rapid 5-minute test that allows clinicians to check the biopsy specimens are sufficient for analysis, during the procedure.

    verifi LUNG workstation, sample vials and portable reader
  • One biopsy, not two.

    Confirming the sample before the procedure ends means fewer repeat biopsies, less waiting for patients and families, and a faster path to treatment.

    verifi LUNG sample collection device

1 Ishiwata et al., CHEST 2023  ·  2 American Cancer Society, 2026  ·  3 Khorana et al., PLoS One 2019

How the verifi LUNG test works

From biopsy to answer in about 5 minutes, without the specimen leaving the procedure room.

verifi LUNGReady Reading… Sufficient

*Products not FDA cleared or approved in any jurisdiction